DAX24.418 -1,2%Est505.983 -1,2%MSCI World4.343 -0,1%Top 10 Crypto9,6500 -2,5%Nas24.404 -0,3%Bitcoin64.500 +2,5%Euro1,1789 ±0,0%Öl95,48 +3,3%Gold4.830 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SAP 716460 Lufthansa 823212 NVIDIA 918422 Siemens Energy ENER6Y NEL ASA A0B733 Deutsche Telekom 555750 Infineon 623100 Commerzbank CBK100 Mercedes-Benz Group (ex Daimler) 710000 Microsoft 870747 ITM Power A0B57L Deutsche Bank 514000 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nahost-Konflikt im Blick: DAX-Handel endet in Rot -- US-Börsen wenig bewegt -- Alphabet verhandelt mit Marvell über KI-Chips -- Psychedelika-Titel, NEL Power, BYD, DroneShield, Siemens Energy im Fokus
Top News
Kryptowährung Ethereum: BitMine hält jetzt vier Prozent aller ETH-Coins - Tom Lee mit Mega-Prognose Kryptowährung Ethereum: BitMine hält jetzt vier Prozent aller ETH-Coins - Tom Lee mit Mega-Prognose
Tesla-Aktie schwächelt: Warum Top-Analyst Dan Ives trotzdem zum Einstieg rät Tesla-Aktie schwächelt: Warum Top-Analyst Dan Ives trotzdem zum Einstieg rät
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ampliphi Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
10,60 EUR +0,80 EUR +8,16 %
BMN
12,52 USD +1,02 USD +8,87 %
BTT
finanzen.net zero
Ampliphi Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.358,20 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PKLC

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS04216R1023

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolARMP

Ampliphi Biosciences Aktien News

DatumMeistgelesen
PR NewswireArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Wer­bungAmpliphi Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
PR NewswireArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
PR NewswireArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
PR NewswireArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
PR NewswireArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa...
PR NewswireArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
PR NewswireArmata Pharmaceuticals Announces Structural Biology Publication
PR NewswireArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
PR NewswireArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
PR NewswireArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ...
PR NewswireArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
PR NewswireArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
PR NewswireArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
PR NewswireArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
PR NewswireArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
PR NewswireArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
PR NewswireArmata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
PR NewswireArmata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
PR NewswireArmata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
PR NewswireArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
PR NewswireArmata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Ampliphi Biosciences News

Ampliphi Biosciences News: auf dieser Seite finden Sie alle Ampliphi Biosciences News und Nachrichten zur Ampliphi Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ampliphi Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ampliphi Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.